News

Everyday Health on MSN18h
When Non-Small Cell Lung Cancer Spreads: What to Expect
What to know about new diagnostic tools, targeted medications, and other recent advances in the treatment of metastatic NSCLC ...
Macau Business12h
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements ...
Targeted Oncology1d
First-Line Treatment Approaches for EGFR-mutated Metastatic NSCLC: Updates from MARIPOSA High-Risk Analyses
An expert discusses a treatment approach for the patient case above, how factors like brain metastases influence first-line treatment choices, reviews high-risk/CNS outcomes data from MARIPOSA and ...
Targeted Oncology1d
An Academic Perspective to Making First-Line Treatment Decisions for EGFR-mutated Metastatic NSCLC
An expert discusses treatment goals for patients with EGFR-mutated advanced/metastatic NSCLC, how to approach combination therapy with high-risk patients, and how recent data has influenced their ...
CURE1d
Diving Into Every FDA Drug Approval for Cancer Care During May 2025
Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.
Clinical Trials Arena on MSN3d
ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons
AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...
Open Access Government3d
Lung cancer drug aumolertinib approved after major trial success
The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...
DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Ca…
Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with ...
Pharmabiz1d
Innovent Biologics presents data from phase 1 PoC study of IBI363 to treat advanced NSCLC at 2025 ASCO
Innovent Biologics presents data from phase 1 PoC study of IBI363 to treat advanced NSCLC at 2025 ASCO: San Francisco Friday, June 6, 2025, 18:00 Hrs [IST] Innovent Biologics, Inc ...
Oncology Nurse Advisor11d
FDA Approves Emrelis for High c-Met Protein Overexpressing NSCLC
RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.
PD-1+ NSCLC Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The leading PD-1+ NSCLC Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others. Promising PD-1+ ...
Pharmabiz3d
UK MHRA approves SFL Pharmaceuticals’ aumolertinib to treat non-small cell lung cancer
UK MHRA approves SFL Pharmaceuticals’ aumolertinib to treat non-small cell lung cancer: United Kingdom Wednesday, June 4, 2025, 11:00 Hrs [IST] The Medicines and Healthcare prod ...